Lizza Hendriks, MD, PhD, Maastricht University, Maastricht, Netherlands, talks on immunotherapy (IO) for non-small cell lung cancer (NSCLC). Durvalumab has shown to improve progression-free survival (PFS) and overall survival (OS) and reduce the rate of brain metastasis in patients with NSCLC. However, patients with metastatic disease, especially those with oncogenic drivers associated with non-smoking, have not demonstrated benefit with IO. Dr Hendrick’s emphasizes tailoring adjuvant IO according to the status of the tumor, as indicated by recently published retrospective data. This interview took place during the virtual European Lung Cancer Congress 2022.

свернуть